Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction

NCT01305226 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT01305226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01305226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
August 31, 2011
Enrollment
120 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction